U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
|
February 10, 2016 |
Re: Notice of disclosure filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act
Dear Sirs,
Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that Novo Nordisk A/S has made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended December 31, 2015, which was filed with the Securities and Exchange Commission on February 10, 2016.
Sincerely,
| /s/ Lars Rebien Sørensen | /s/ Jesper Brandgaard | |
|
Lars Rebien Sørensen President and Chief Executive Officer
|
Jesper Brandgaard Executive Vice President and Chief Financial Officer |
Novo Nordisk A/S
|
Novo
Allé
|
Telephone: +45 4444 8888
Telefax: +45 4444 6626 |
Internet: novonordisk.com
CVR Number: 24256790 |